In Depth 31 Jan 2024 New epilepsy drugs: what is in the pipeline? …a global phase 3 program. Cell therapy candidate for drug-resistant epilepsy Based in South San Francisco, biotech company Neurona Therapeutics is currently developing an allogeneic cell therapy candidate for the… January 31, 2024 - 6 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 26 Jan 2023 First patient treated in Atrogi type 2 diabetes clinical study Atrogi AB, an early-stage Swedish pharma company, has announced that the first patient has been enrolled in a phase 1a/b study. Atrogi’s drug candidate, ATR-258 is a first in class… January 26, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 16 Nov 2023 uniQure: is the gene therapy pioneer en route to becoming a biotech rebuff? …candidate sees mixed results, uniQure stocks drop In the meantime, uniQure was invested in bringing its Huntington’s disease candidate to the market. AMT-130 consists of an adeno-associated virus serotype 5… November 16, 2023 - 7 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 14 Mar 2024 Rett syndrome: advances in gene therapy brings hope …is done by regulating the gene’s expression on a cell-by-cell basis. The candidate TSHA-102 is designed to mediate levels of MeCP2 proteins in the central nervous system without the risk… March 14, 2024 - 8 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 25 Jun 2025 ALS: how close are we to a cure? …patients, or slow disease progression. Even preclinical treatments such as the gene therapy candidate VY9323 have stumbled, but for different reasons. Massachusetts-based Voyager Therapeutics reported that its SOD1 gene-silencing candidate… June 25, 2025 - 12 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 31 Mar 2021 Lava Therapeutics’ IPO Shakes Cancer Niche of Gamma Delta T Cells …based on immune cells known as gamma delta T cells. The proceeds of the IPO will be used to drive the development of the company’s pipeline of bispecific antibody drugs,… March 31, 2021 - 5 minutesmins - By Anita Chakraverty Share WhatsApp Twitter Linkedin Email
Interview 10 May 2021 The Rollercoaster of Repurposing an Arthritis Drug for Covid-19 …position. Shortly after, the company started a program for Covid-19 based on its rheumatoid arthritis drug candidate. With the help of COO Malin Berthold, who had joined Cyxone in August… May 10, 2021 - 8 minutesmins - By Larissa Warneck-Silvestrin Share WhatsApp Twitter Linkedin Email
More News! 23 Jul 2024 First AKT-targeting drug capivasertib to hit the market, could it open the door for more? …clinical trials? Here are a couple of promising candidates in the AKT inhibitor space: Taiho Pharmaceuticals’ TAS-117 Currently in phase 1 clinical trials and tested in patients with advanced solid… July 23, 2024 - 7 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
News and Trends 26 Jan 2021 Oxford’s Covid-19 Vaccine Blazes Trail for Oncolytic Virus Firms …advanced candidate — a liver cancer treatment developed by the French biotech Transgene — was abandoned in phase III in 2019. Why have new oncolytic viruses been slow to reach… January 26, 2021 - 7 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Startup Scout 23 Jun 2017 This Newly Founded French Biotech is All About Vaccines This week we visited the biotech hub Lyon, where one of our top biotechs Imaxio has recently founded Osivax to advance the development of its innovative vaccine candidates. Mission: Osivax… June 23, 2017 - 1 minutemin - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 30 Jun 2017 €40M in Series C for a British Biotech Treating Blindness with Gene Therapy …advanced is Spark Therapeutics, in the US, which expects FDA approval for its lead candidate in retinal disease this year. A second candidate, SPK-7001, is in Phase I/II for choroidemia,… June 30, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
In Depth 25 Jul 2024 The future of inflammatory bowel disease treatment: what is on the horizon? …– Howard University AbbVie’s interest in IBD treatments isn’t waning. Last month, it bought up a preclinical candidate from Chinese biopharma FutureGen Biopharmaceutical for $150 million. The candidate FG-M701 inhibits… July 25, 2024 - 8 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email